Orbus Therapeutics Inc.

Orbus Therapeutics, Inc. primary focus is the development of therapeutic products that treat patients suffering from rare diseases for which there are few available effective therapies. Currently, Orbus is working to develop and commercialize eflornithine in North America. Eflornithine is a novel cytostatic (growth-inhibiting) agent, which we are developing for the treatment of patients with anaplastic astrocytoma (AA). Eflornithine slows tumor growth by inhibiting the production of an enzyme, ornithine decarboxylase (ODC), a key enzyme associated with cell growth and proliferation.We at Orbus are committed to bringing innovative products to the underserved patients affected by rare diseases. We are focused and passionate about achieving more positive outcomes for patients facing life-threatening or significantly life-altering diseases. As we approach the end of enrollment for our Phase 3 clinical trial with eflornithine (the STELLAR study), we are very excited about the future and welcome inquiries from potential strategic partners. For more information about our product candidate or our company.
Visit us online at http://www.orbustherapeutics.com/
Email us directly at info@orbustherapeutics.com... More Info Less Info